Aeris Biotechnologies

Aeris Biotechnologies

Early Stage

A Groundbreaking Approach to Asthma & Allergy

A Groundbreaking Approach to Asthma & Allergy

Overview

Raised this Round: Raised: $95,200

Total Commitments ($USD)

Platform

Dalmore Group

Start Date

07/25/2022

Close Date

Not Provided

Min. Goal
$500
Max. Goal
$15,000,000
Min. Investment

$500

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$28,350,000

Year Founded

2021

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

Medium

Capital Intensity

High

Location

Plano, Texas

Business Type

Growth

Aeris Biotechnologies is raising funds through Reg A+ crowdfunding with Dalmore Group as the Broker-Dealer. The company is bringing an innovative and green approach to the treatment of asthma. The business has developed a first-of-its-kind, in-home, and affordable treatment kit to control the dust mites and associated allergens that cause asthma. The technology of Aeris Biotechnologies is green, scalable, and patent-protected. Aaron Michael Gunn and Dr. David Richard Harper founded Aeris Biotechnologies in 2021. The current crowdfunding campaign has a maximum target of $15,000,000. The campaign proceeds will be used for business development, marketing, research and development, product development, and working capital.

Balance Sheet

Cash and Cash Equivalents

$33,242

Total Assets

$33,242

Accounts Payable & Accrued Liabilities

$104,548

Long Term Debt

$50,000

Total Liabilities

$104,548

Total Stockholders' Equity

$-71,306

Total Liabilities and Equity

$33,242

Statement of Comprehensive Income Information

Net Income

$0

Earnings Per Share - Basic

$0.00

Earnings Per Share - Diluted

$0.00

Auditor: BF Borgers CPA PC
Financials as of: 07/25/2022
Create a free account today to gain access to Kingscrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Aeris Biotechnologies on Dalmore Group 2022
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $28,350,000
Price per Share: $1.00

Follow company

Follow Aeris Biotechnologies on Dalmore Group 2022

Buy Aeris Biotechnologies's Deal Report

Warning: according to the close date for this deal, Aeris Biotechnologies may no longer be accepting investments.

Aeris Biotechnologies Deal Report

Get Kingscrowd's comprehensive report on Aeris Biotechnologies including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Aeris Biotechnologies is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Aeris Biotechnologies deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge